



MaaT Pharma and Skyepharma announce their partnership to launch the first French factory of production exclusively dedicated to biotherapies issues microbiota

- This partnership will allow at MaaT Pharma of dispose of one site dedicated with a area of 1,500m² that can be multiplied by two if necessary, to increase its industrial production capacity pharmaceutical standards (cGMP) and so to support the development clinical then commercial of his of them candidates- medications the more advances (MaaT013 and MaaT033) and to speed up his activity R&D and of development clinical on the products of news generation (MaaT03x).
- MaaT Pharma will deploy a factory entirely dedicated at the production of biotherapies based on complete ecosystem microbiota (<< *“Microbiome Ecosystem Therapies”* >> or MET) and will be the first business resident from SkyeHub Bioproduction of Skypharma.
- This first factory dedicated to ecosystems complete could be able to allow at the France of to strenghten her capacity of production on the territory, in to endowing of one new siteof bioproduction in France integrating from technology of breakup.

Lyons and Saint-Quentin-Fallavier, France, 8 February 2022 – 6:00 p.m. THIS- [MaaT Pharma](#) (EURONEXT: MAAT - the "Company"), a French clinical-stage biotechnology company advanced (Phase 3), pioneer in the development of drugs in the restoration microbiota intestinal to improve the survival of cancer patients, and [Skypharma](#), company CDMO² specialized in the formulation and the manufacturing of medications complex and at release controlled, announce today the signature of one partnership to build the factory, to date, the largest in France entirely dedicated at the production of therapies at ecosystem full issues from microbiota, in respect for standards cGMP³. The site will be implanted in the region Lyonnaise (Saint-Quentin-Fallavier) with an area of 1,500m², which could be increased to 3,000m² depending on the production needs of MaaT Pharma. The plant will allow MaaT Pharma of multiply through ten her capacity of production of way at to support the plan clinical and commercial of the Society at horizon 2030.

The aim of this site will be to produce annually up to several thousand units of MaaT013, drug candidate the more advanced (formulation liquid) of the Society dedicated to treatment of graft versus host disease, and several hundred thousand capsules of its second product, MaaT033 intended to improve patient survival receiving an allogeneic stem cell transplant. Part of the site will also be dedicated, by 2030, to the deployment of R&D and clinical production of the new generation of drug candidates (MaaT03X) using the technology innovative of co- MaaT Pharma ecosystem fermentation to improve treatment responses through immunotherapy.

*“As we enter Phase 3 of our most advanced drug candidate, MaaT013, the agreement signed with Skyepharma allows us to start increasing our capacity of production for to respond at term to needs from launch commercial. We can so to consider serenely expansion of our wallet of candidates- innovative drugs for cancer patients” commented **Hervé Affagard, co-founder and managing director of MaaT Pharma** . “This partnership is fully in line in ambition displayed, in the framework from Health Innovation 2030 plan, to become a nation at the forefront of biotherapies and independent for bioproduction. industry nascent microbiota opens up a great opportunity for France to position itself from today in leader. »*

David Lescuyer, Managing Director of Skyepharma, added *“The SkyeHub will enable to increase cGMP production capacity in France for medicinal products based on microbiota. Our partnership is a value accelerator, each company bringing his know how and his expertise. »*

Under the terms of the agreement, which follows a bilateral letter of intent signed in September 2021 and whose financial conditions remain confidential, MaaT Pharma will have of one building dedicated, of which the construction will be funded through skyepharma to breast from SkyeHub Bioproduction. It is expected that the plant, whose planned commissioning is expected for 2023, hosts MaaT proprietary teams and equipment Pharmaceuticals. Within this framework, the Lyon biotech will control and supervise R&D as well as the production clinical and commercial of his wallet diversified of candidates- medicines in its various forms (formulations for enemas and oral capsules). In addition to the provision of the building meeting the quality standards in force (cGMP), skyepharma will bring his expertise in matter of standards of quality from products, regulatory affairs, certification and large-scale production. This new production site will also allow MaaT Pharma to accelerate the development of his products news generation MaaT03X using a technology owner unique of complete ecosystem co-fermentation, for which the Company recently received two financing public in the framework from Plan France Relaunch and from 4th - Program of investments future (PIA4). This news class matches at from MET oral constituted of hundreds cash, configured custom made on the based of data clinics.

AT about of MaaT Pharma

MaaT Pharma is a clinical-stage biotechnology company that has developed a comprehensive approach to restore the microbiota/host symbiosis of cancer patients. Committed to processing cancers and graft-versus-host disease (GvH), a serious complication occurring after a transplant of hematopoietic stem cells, MaaT Pharma has already carried out the proof of concept of its approach in patients with acute myeloid leukemia and in a phase 2 clinical trial in acute GvH. For to support the development of his wallet of products and his extension at from directions more wide, MaaT Pharma has developed gutPrint®, a powerful discovery and analysis platform for determining new therapeutic targets, evaluate drug candidates and identify biomarkers in the socket in charge pathologies involving the microbiota.

Microbiome Ecosystem Therapies developed by MaaT Pharma can to be administered through enema Where encapsulated for a administration oral. They are all produced under highly standardized cGMP manufacturing and quality controls to ensure safe access to the diversity and richness of the microbiome. MaaT Pharma benefits from the commitment of scientists of fame world and of relationships established with the instances regulatory for to be the iron of spear from profits therapeutic of the modulation from microbiota from patients and of his integration in the convenient clinical.

MaaT Pharma is listed on Euronext Paris (Coded mnemonic : MAAT).



AT about of skyepharma

Skyepharma is an independent French pharmaceutical CDMO company, 100% owned by its team of management and Bpifrance. skyepharma is specialized in the formulation, the development and the production of pharmaceutical products for the oral route (tablets, capsules, powders), with expertise particular and from technology owners for the shapes complex and at release modified. skyepharma is located in Saint-Quentin-Fallavier (Isère), on a 60,000m² site. The current factory, dedicated to the activity on solid oral forms occupies 22,000m². Skyepharma has decided to make the available land available (more of 20 000m²) for the bet in square from SkyeHub Bioproduction. the model from SkyeHub is destined at to offer production capacities of clinical and commercial batches to Biomedicine companies, under the form of an offer including the construction of dedicated factories, surfaces and premises specifically adapted to processes and products from companies partners and of services accompanying adjusted (quality, maintenance, release batches, etc.).

contacts

MaaT Pharma – Relationshipsinvestors

Hervé AFFAGARD, Co-founder and
Director General
Siân CROUZET, Director
Administrative and
financial
+33 4 28 29 14 00
invest@maat-pharma.com

MaaT Pharma – Relationships media

Paulina RICHAUD
Senior PR & Corporate Communications
Manager
+33 6 07 55 25 36
prichaud@maat-pharma.com

Trophic Communications corporate communicationsand medical

Jacob VERGHESE
Where Gretchen
SCHWEITZER
+49 89 23 88 77 31
maat@trophic.eu

skyepharma

Laurent RIGAUDEAU
Marketing Director
andcommercial
+33 (0) 6 30 49 22 82
L.rigaudeau@skyepharma.fr

Data prospective

This press release contains forward-looking statements. All statements other than statements of historical fact included in this press release regarding future events are prone at (i) from changes without prior notice and (ii) from factors independent of the will of the Society. Those

statements may include, but are not limited to, any statement preceded, followed by, or including words such as "target", "believe", "expect", "aim", "intend", "can", "plan", "estimate", "plan », "project », "to want », "to be able to have », "susceptible of », "likely », "duty », "forecasts and other words and terms with a similar meaning or the resulting negative form. statements forward-looking statements are subject to inherent risks and uncertainties beyond the control of the Company which could cause the actual results or performance of the Company to differ considerably from results Where from performance expected cast Where implied in those statements prospective.

¹ Microbiome ecosystem Therapy = Microbiotherapy at ecocostema full

² contract Development & Manufacturing organization, manufacturing & development in outsourcing

³ cGMP (current good production practice) = Good Practice of Manufacturing (GMP)